Axogen Expands RECON Study Of Avance Nerve Graft
The study will be expanded by 50 patients, for a total of 220 subjects, based on the recommendation of a statistician who reviewed an interim analysis. RECON is intended to support a Biologic License Application for Avance, a processed human nerve allograft for bridging severed peripheral nerves.
You may also be interested in...
Supported by results from the RECON trial, the Florida company will file a biologics license application for its Avance nerve graft used surgical repair of finger injuries
Starts & Stops: Boston Scientific Launches New Lotus TAVR Trial, Medtronic Starts Study Of SynchroMed II Pain Pump
Starts & Stops compiles all the clinical trial announcements, initiations, completions and suspensions tracked by MedDeviceTracker. This edition covers trial announcements from Jan. 7 through Jan. 27, including announcements from Medtronic, QT Vascular, Boston Scientific, and Shockwave.
Navitor is an upgraded version of Abbott’s Portico TAVR system with a better fabric cuff and large curved aortic “cells” to reduce the risk of injury to the native valve.